Crinetics to Present Atumelnant and Paltusotine Updates at ENDO 2024

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) has announced that five abstracts from its clinical programs, including four late-breaking abstracts, will be presented at the Endocrine Society’s annual meeting, ENDO 2024, to be held from June 1-4, 2024, in Boston, Massachusetts.

According to Scott Struthers, Ph.D., the founder and CEO of Crinetics, this year's meeting is significant as it will feature initial findings from two studies of the investigational drug atumelnant (CRN04894), an oral ACTH receptor antagonist. The studies target treatments for classic congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing’s syndrome. Additionally, the meeting will showcase data from Phase 3 trials of paltusotine for acromegaly, with the company aiming to submit a new drug application for paltusotine later this year.

Two poster presentations will focus on clinical data for atumelnant. The first will highlight initial safety and key biomarker efficacy findings in CAH, including rapid and significant reductions in androstenedione (A4) and 17-hydroxyprogesterone levels from the Phase 2 open-label TouCAHn study. The second will present data from a Phase 1b/2a open-label single-center study in ACTH-dependent Cushing’s syndrome, showing the first evidence of rapid and sustained cortisol reductions.

Crinetics will also present data from the Phase 3 PATHFNDR-2 study evaluating paltusotine in acromegaly patients who were medically untreated. Another poster will feature data from the PATHFNDR-1 study involving previously treated acromegaly patients who switched to paltusotine from injected somatostatin receptor ligands. This includes a new analysis of patient-reported symptoms. Additionally, data from the PATHFNDR program will be discussed in a Science and Innovation Theater session led by Dr. Kevin C.J. Yuen on June 1, 2024, titled “Paltusotine: A Novel, Investigational Oral Small Molecule Somatostatin Receptor Ligand for Acromegaly.” A third presentation will provide long-term safety and efficacy updates from the Phase 2 ACROBAT Advance open-label extension study.

Details on the presentations are as follows:

1. "Once Daily Oral Atumelnant (CRN04894) Induces Rapid and Profound Reductions of Androstenedione and 17-hydroxyprogesterone in Participants with Classical Congenital Adrenal Hyperplasia: Initial Results from a 12-Week, Phase 2, Open-Label Study" - June 3rd from 12:00 – 1:30 pm ET, Session P108, Late-Breaking Poster Presentations, ENDOExpo Poster Area, BCEC.

2. "Atumelnant (CRN04894) Induces Rapid And Sustained Reductions In Serum And Urine Cortisol In Patients With ACTH-dependent Cushing Syndrome During A Phase 1b/2a, Single Center, 10-day, Inpatient, Open-label Study" - June 3rd from 12:00 – 1:30 pm ET, Session P108, Late-Breaking Poster Presentations, ENDOExpo Poster Area, BCEC.

3. "Efficacy and Safety of Once-Daily Oral Paltusotine in Medically Untreated Patients With Acromegaly: Results from the Phase 3, Randomized, Placebo-Controlled PATHFNDR-2 Study" - June 3rd from 12:00 – 1:30 pm ET, Session P108, Late-Breaking Poster Presentations, ENDOExpo Poster Area, BCEC.

4. "Use of the Acromegaly Symptom Diary (ASD) in a Phase 3, Placebo-Controlled Study of Once-Daily, Oral Paltusotine in Patients With Acromegaly Switched From Injected Octreotide or Lanreotide" - June 3rd from 12:00pm – 1:30 pm ET, Neuroendocrinology and Pituitary: Pituitary Tumors IV, ENDOExpo Poster Area, BCEC.

5. "Long-Term Safety and Efficacy of Once-Daily Oral Paltusotine in the Treatment of Patients With Acromegaly: Update From ACROBAT Advance" - June 3rd from 12:00 – 1:30 pm ET, Session P108, Late-Breaking Poster Presentations, ENDOExpo Poster Area, BCEC.

The poster presentations will be available on the Crinetics website at the time of presentation, following the ENDO embargo policy.

Atumelnant (CRN04894) is an investigational oral ACTH receptor antagonist targeting the melanocortin type 2 receptor on the adrenal glands. It is in Phase 2 studies for CAH and ACTH-dependent Cushing’s syndrome.

Paltusotine is an oral, once-daily, selectively-targeted somatostatin receptor type 2 agonist. It has completed Phase 3 studies for acromegaly and Phase 2 studies for carcinoid syndrome. Paltusotine aims to provide a convenient, effective daily treatment option for acromegaly and carcinoid syndrome patients.